Programming of radiotherapy in the treatment of non-small-cell lung cancer - a way to advance care

Lancet Oncology

Volumn 2, Issue 7, 2001, Pages 401-408

  Saunders, M I ^a  

^a Mt Vernon H   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED RADIOTHERAPY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; RADIATION TOLERANCE; RADIOBIOLOGY; RADIOTHERAPY, CONFORMAL;

EID: 0035411301     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00417-4     Document Type: Review

References (49)

1. Hansen H.H., Goldstraw P., Gregor A., Vindelov L. Tumours of the trachea and lung. Peckham M., Pinedo H.M., Veronesi U. The Oxford textbook of oncology. 2:1995;1533-1557 Oxford University Press, New York.
2. Thames H.D., Hendry J.H. In hindsight. Thames H.D., Hendry J.H. Fractionation in radiotherapy. 38:1987;137-169 Taylors and Francis, London.
3. Coutard H. Roentgentherapy of epitheliomas of the tonsillar region, hypopharynx, and larynx from 1920 to 1928. Am J Roentgenol 1932; 28: 313-31 and 243-8.
4. Fowler J. F., Lindstrom M. J. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 23:1992;3457-3467.
5. Cox J., Pajak T., Asbell S., et al. Interruptions of high dose radiation therapy decrease long term survival of favorable patients with unresectable non small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 27:1993;493-498.
6. Perez C., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer. 45:1980;2744-2753.
7. Perez C., Stanley K., Grundy G., et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer. 50:1982;1091-1099.
8. Perez C., Bauer M., Edelstein S., Gillespie B., Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 12:1986;539-547.
9. Thames H.D., Hendry J.H. Radiation-induced injury to tissues. Fractionation in radiotherapy. 1987;1-21 Taylors and Francis, London.
10. Withers H.R., Thames H.D., Peters L.J. Differences in the fractionation response of acutely and late-responding tissues. Karcher K.H., Kogelnik H.D., Reinartz G. Progress in radio-oncology II. 1982;287-296 Raven Press, New York.
11. Thames H., Withers H., Peters L., Fletcher G. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 8:1982;219-226.
12. Barendsen G.W. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 8:1982;1981-1997.
13. Douglas B., Fowler J. The effect of multiple small doses of X rays on skin reactions in the mouse and a basic interpretation. Radiat Res. 66:1976;401-426.
14. Ang K.K., Thames H.D., van der Kogel A.J., van der Schueren E. Is the rate of repair of radiation-induced sublethal damage in rat spinal cord dependent on the size of dose per fraction? Int J Radiat Oncol Biol Phys. 13:(4):1987;557-562.
15. Ruifrok A.C.C., Kleiboer B.J., van der Kogel A.J. Fractionation sensitivity of the rat cervical spinal cord during radiation retreatment. Radiother Oncol. 25:1992;295-300.
16. Landuyt W., Fowler J., Ruifrok A., Stuben G., van der Kogel A., van der Schueren E. Kinetics of repair in the spinal cord of the rat. Radiother Oncol. 45:1997;55-62.
17. Bentzen S., Saunders M., Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 53:1999;219-226.
18. Steele J.D., Buell P. Asymptomatic solitary pulmonary nodules: host survival, tumour site and growth rate. J Thorac Cardiovasc Surg. 65:1971;140-151.
19. Wilson G.D., McNally N.J., Dische S., et al. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer. 58:1988;423-431.
20. Cox J., Pajak T., Marcial V., et al. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of Radiation Therapy Oncology Group protocol 83-13. Int. J Radiat Oncol Biol Phys. 18:1990;515-521.
21. Cox J., Azarnia N., Byhardt R., Shin K., Emami B., Pajak T. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with >69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:(9):1990;1543-1555.
22. Byhardt R.W. Hyperfractionation. Pass H.I., Mitchell J.B., Johnson D.H., Turrisi A.T. Lung Cancer: Principles and Practice. 1996;711-719 Lippincott-Raven, Philadelphia.
23. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomised trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage II non-small-cell lung cancer. N Engl J Med. 323:1990;940-945.
24. Sause WT, Scott CB, Taylor S. Radiation Therapy Oncology Group (RTOG 88-08) Eastern Cooperative Oncology Group (ECOG 4588): Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow-up. Int J Radiat Oncol Biol Phys. 32:1995;109. Abstr.
25. Sause W., Kolesar P., Taylor S., et al. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer. RCOG, ECOG and SWOG. Chest. 117:2000;2358-2364.
26. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 326:1992;524-529.
27. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for Stage III non-small-cell lung cancer: A randomized study. J Clin Oncol. 14:1996;1065-1070.
28. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Oncology Group (RTOG) 9410. Lung Cancer. 29:2000;303. Abstr.
29. Horiot J., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 25:1992;231-241.
30. Ball D., Bishop J., Smith J., et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multicentre trial. Radiother Oncol. 52:1999;129-136.
31. Byhardt R.W., Pajak T., Emani B., Herskovic A., Doggett R., Olsen L. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys. 26:1993;459-468.
32. Sun L.-m, Wan Laung S., Wang C-J. Comcomitant boost radiation therapy for inoperable non-small cell lung cancer: preliminary report of a prospective randomised study. Int J Radiat Oncol Biol Phys. 47:2000;413-418.
33. Fu K., Pajak T., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: preliminary results of RTOG 9003. Int J Radiat Oncol Biol Phys. 48:2000;7-16.
34. Saunders M., Dische S., Fowler J., et al. Radiotherapy employing 3 fractions on 12 consecutive days. Acta Oncol. 27:1988;163-168.
35. Saunders M., Dische S. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys. 19:1990;1211-1215.
36. Saunders M., Dische S., Barrett A., et al. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. Br J Cancer. 73:1996;1455-1462.
37. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet. 350:1997;161-166.
38. Saunders M., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. Radiother Oncol. 52:(2):1999;137-148.
39. Ball D., Peters L.J., Smith J. Letter to Radiother Oncol. 58:2001;91-92.
40. Bentzen S.M., Saunders M.I., Dische S., et al. Accelerated radiotherapy vs chemoradiation in non-small cell lung cancer: Quantifying the hazards. Radiother Oncol. 58:2001;91-92.
41. Bailey A.J.P.M., Stephens R.J. Patient-reported short-term and long-term physical and psychological symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomised trial in non-small cell lung cancer. J Clin Oncol. 16:(9):1998;3082-3093.
42. Guidance on commissioning cancer services, improving outcomes in lung cancer. The Manual, NHS Executive. 1998; 6.
43. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 311:1995;899-909.
44. Oral E.N., Bavbek S., Kizir A., et al. Preliminary analysis of a phase II study of Paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer. 25:1999;191-198.
45. Saunders M.I., Rojas A., Lyn B.E., et al. Experience with dose escalation using CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) in non-small cell lung cancer. Br J Cancer. 78:1998;1323-1328.
46. Herskovic A., Orton C., Seyedsadr M., et al. Initial experience with a practical hyperfractionated accelerated radiotherapy regimen. Int J Radiat Oncol Biol Phys. 21:1991;1275-2181.
47. Bernier J., Denekamp J., Rojas A., et al. ARCON: accelerated radiotherapy with carbogen andnicotinamide in non-small cell lung cancer: a phase I/II study by the EORTC. Radiother Oncol. 52:1999;149-156.
48. Treat J., Johnson E., Langer C., et al. Tirazemine with cisplatin in patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol. 16:1998;3524-3527.
49. Brizel D.M., Wasserman T.H., Strnad V., et al. Final report of a phase III randomised controlled trial of Amifostine as a radioprotectant in head and neck cancer. Int J Radiat Oncol. 45:1999;145-148.